Royalty Pharma Acquires Royalty Interest in Alnylam’s Amvuttra for $310 Million from Blackstone Life Sciences

NEW YORK, NY, DECEMBER 16, 2025 – Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a pre-existing royalty interest in Nuvalent’s neladalkib and zidesamtinib from an undisclosed third party for up to $315 million

NEW YORK, NY, and SOUTH SAN FRANCISCO, CA, DECEMBER 4, 2025 – Royalty Pharma plc (Nasdaq: RPRX) and Denali Therapeutics, Inc. (Nasdaq: DNLI) today announced a $275 million synthetic royalty funding agreement based on future net sales of tividenofusp alfa.

NEW YORK, NY, and CAMBRIDGE, MA NOVEMBER 4, 2025 – Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a royalty interest in Alnylam’s AMVUTTRA from funds managed by Blackstone Life Sciences (“Blackstone”) for $310 million. The royalty interest being sold stems from Blackstone’s 2020 financing collaboration with Alnylam, in which Blackstone invested to support AMVUTTRA’s pivotal Phase 3 HELIOS-B trial.